Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends : Analysis of the SEER database
Published by Elsevier Ltd..
OBJECTIVE: Evaluate current practice patterns in the use of adjuvant radiation for T1-2N1 OCSCC patients and investigate its efficacy in the population-based setting.
MATERIALS AND METHODS: This study extracted patients who were treated surgically for T1N1 and T2N1 OCSCC without adverse nodal features from the SEER database from 2004 to 2013. Patients with distant metastatic disease, unknown surgery or radiation status, or prior malignancies were excluded. Patients were divided into those who underwent surgical resection with and without adjuvant radiation. Disease-specific survival (DSS) and overall survival (OS) were the primary outcomes measured.
RESULTS: 746 patients met inclusion criteria and 70% received adjuvant radiation therapy. Treatment with adjuvant radiation therapy was significantly associated with improved 5-year DSS (65% versus 51%; p < 0.001) and OS (54% versus 44%; p = 0.007) for T1N1 tumors. Likewise, improved 5-year DSS (58% versus 38%; p = 0.009) and OS (48% versus 28%; p = 0.004) was shown in T2N1 tumors. Patients with T2N1 tumors wer significantly more likely to receive adjuvant radiation (75% versus 63%; p < 0.001). Those with insurance and high risk primary subsites: buccal, retromolar trigone, and hard palate were more likely to receive adjuvant radiation. The percent utilization of adjuvant radiation remained constant through the study period for T2N1 tumors (72-74%) but significantly decreased for T1N1 (71-55%) (p = 0.047).
CONCLUSION: Adjuvant radiation therapy is independently associated with a significant survival benefit for patients with both T1N1 and T2N1 OCSCC. However, this study demonstrates that patients with T1N1 cancer are less likely to receive adjuvant radiation and utilization is decreasing.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
Oral oncology - 85(2018) vom: 17. Okt., Seite 1-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Torrecillas, Vanessa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvant radiation |
|---|
| Anmerkungen: |
Date Completed 22.11.2019 Date Revised 03.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.oraloncology.2018.07.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM28857169X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM28857169X | ||
| 003 | DE-627 | ||
| 005 | 20231225060620.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2018.07.019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0961.xml |
| 035 | |a (DE-627)NLM28857169X | ||
| 035 | |a (NLM)30220313 | ||
| 035 | |a (PII)S1368-8375(18)30278-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Torrecillas, Vanessa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends |b Analysis of the SEER database |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2019 | ||
| 500 | |a Date Revised 03.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Elsevier Ltd. | ||
| 520 | |a OBJECTIVE: Evaluate current practice patterns in the use of adjuvant radiation for T1-2N1 OCSCC patients and investigate its efficacy in the population-based setting | ||
| 520 | |a MATERIALS AND METHODS: This study extracted patients who were treated surgically for T1N1 and T2N1 OCSCC without adverse nodal features from the SEER database from 2004 to 2013. Patients with distant metastatic disease, unknown surgery or radiation status, or prior malignancies were excluded. Patients were divided into those who underwent surgical resection with and without adjuvant radiation. Disease-specific survival (DSS) and overall survival (OS) were the primary outcomes measured | ||
| 520 | |a RESULTS: 746 patients met inclusion criteria and 70% received adjuvant radiation therapy. Treatment with adjuvant radiation therapy was significantly associated with improved 5-year DSS (65% versus 51%; p < 0.001) and OS (54% versus 44%; p = 0.007) for T1N1 tumors. Likewise, improved 5-year DSS (58% versus 38%; p = 0.009) and OS (48% versus 28%; p = 0.004) was shown in T2N1 tumors. Patients with T2N1 tumors wer significantly more likely to receive adjuvant radiation (75% versus 63%; p < 0.001). Those with insurance and high risk primary subsites: buccal, retromolar trigone, and hard palate were more likely to receive adjuvant radiation. The percent utilization of adjuvant radiation remained constant through the study period for T2N1 tumors (72-74%) but significantly decreased for T1N1 (71-55%) (p = 0.047) | ||
| 520 | |a CONCLUSION: Adjuvant radiation therapy is independently associated with a significant survival benefit for patients with both T1N1 and T2N1 OCSCC. However, this study demonstrates that patients with T1N1 cancer are less likely to receive adjuvant radiation and utilization is decreasing | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adjuvant radiation | |
| 650 | 4 | |a Disease-specific survival | |
| 650 | 4 | |a Improved survival | |
| 650 | 4 | |a Oral cavity cancer | |
| 650 | 4 | |a Overall survival | |
| 650 | 4 | |a Population-based study | |
| 650 | 4 | |a SEER database | |
| 650 | 4 | |a Survival outcomes | |
| 650 | 4 | |a Treatment trends | |
| 650 | 4 | |a Utilization | |
| 700 | 1 | |a Shepherd, Hailey M |e verfasserin |4 aut | |
| 700 | 1 | |a Francis, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Buchmann, Luke O |e verfasserin |4 aut | |
| 700 | 1 | |a Monroe, Marcus M |e verfasserin |4 aut | |
| 700 | 1 | |a Lloyd, Shane |e verfasserin |4 aut | |
| 700 | 1 | |a Cannon, Donald |e verfasserin |4 aut | |
| 700 | 1 | |a Hitchcock, Ying J |e verfasserin |4 aut | |
| 700 | 1 | |a Weis, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Jason P |e verfasserin |4 aut | |
| 700 | 1 | |a Houlton, Jeffrey J |e verfasserin |4 aut | |
| 700 | 1 | |a Cannon, Richard B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oral oncology |d 1998 |g 85(2018) vom: 17. Okt., Seite 1-7 |w (DE-627)NLM091475074 |x 1879-0593 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2018 |g day:17 |g month:10 |g pages:1-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.oraloncology.2018.07.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2018 |b 17 |c 10 |h 1-7 | ||